History and Epidemiology of Male Sexual Dysfunction

Standard Practice in Sexual Medicine

Volumn , Issue , 2008, Pages 43-48

  Porst, Hartmut ^a   Sharlip, Ira D ^b  

^a Neuer Jungfernstieg 6a   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Human behavior; Sexual dysfunction; Sexuality; Social science

Indexed keywords

EID: 84889309114     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755235.ch4     Document Type: Chapter

References (42)

1. Freud S. Über die allgemeinste Erniedrigung des Liebeslebens. Jahrbuch für Psychoanalytische und Psychopathologische Forschungen 1912;4(1):40-50.
2. Spiegel L. Untersuchungen einiger neuer Drogen(I. Yohimbeherinde). Chemiker-Zeitung 1886;97:970-971.
3. Wooten JS. Ligation of the dorsal vein of the penis as a cure for atonic impotence. Tex Med J 1902;16:325-328.
4. Lydston GF. The surgical treatment of impotency: further observations on the resection of the vena dorsalis penis in appropriate cases of impotence in the male with a record of experiences. Am J Clin Med 1908;15:1571-1573.
5. Lederer O. Vorrichtung zur künstlichen Erektion des Penis. Patentschrift Nr. 268874, Klasse 30d, Gruppe 15. Kaiserliches Patentamt 1914. (Available from European patent office, Den Haag, The Netherlands, 1914.)
6. Kinsey AC, Pomeroy WB, Martin CE, eds. Sexual behavior in the human male. Philadelphia: W Saunders Co., 1948.
7. Masters WH, Johnson VE, eds. Human sexual response. Boston: Little Brown and Co., 1966.
8. Masters WH, Johnson VE, eds. Human sexual inadequacy. Boston: Little Brown and Co., 1970.
9. Michal V, Kramar R, Pospichal J. Direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Rozhal Chir 1973;52:587-591.
10. Michal V, Kramar R, Pospichal J, et al. Arterial epigastricocavernous anastomosis for the treatment of sexual impotence. World J Surg 1977;1:515-520.
11. Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973;2:80-82.
12. Small MP, Carrion HM, Gordon JA. Small Carrion penile prosthesis. Urology 1975;5:479-486.
13. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
14. Zorgniotti AW, Lefleur RS. Autoinjection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985;133:39-41.
15. Adaikan PG, Kottegoda SR, Ratnam SS. A possible role for prostaglandin E1 in human penile erection. In:Abstract Book Second World Meeting on Impotence. Abstr.2.6, Prague, 1986.
16. Porst H. Stellenwert von Prostaglandin E1 (PGE) in der Diagnostik der erektilen dysfunktion (ED) im Vergleich zu Papaverin und Papaverin/Phentolamin bei 61 Patienten mit ED. Urologe A 1988;27:22-26.
17. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988;140:66.
18. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 1996;8:47-52.
19. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of Dapoxetine in the treatment of premature ejaculation. J Urol 2005;173:Suppl. 201,740.
20. Melman A, Bar-Chama N, Christ G. The first phase I human gene transfer trial: Ion channel therapy for the treatment of ED-preliminary results. J Sex Med 2004;1:Suppl.1, 141, Abstr. UP 153.
21. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56.
22. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and first medical and psychosocial correlates:Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
23. Dunn KM, Croft PR, Hackett GI. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998;15:519-524.
24. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. Prevalence and Predictors. JAMA 1999;281:537-544.
25. Braun M, Klotz T, Reifenrath B, et al. Die Prävalenz von männlichen Erektionsstörungen in Deutschland heute und in der Zukunft. Akt Urol 2000;31:302-307.
26. Chew KK, Earle CM, Stuckey BGA, et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impotence Res 2000;12:41-45.
27. Akkus E, Kadioglu A, Esen A, et al. The prevalence and correlates of erectile dysfunction in Turkey. Int J Impotence Res 12, 9th World Meeting on Impotence Research, Perth, 2000, M 64, p. 57.
28. Vaaler S, Lövkist H, Svendsen KOB, et al. Prevalence of erectile dysfunction in men over 40 years seeing general practitioners. Int J Impotence Res 2000;12:Suppl.5, S.8:29.
29. Meuleman E, Kolman D, Donkers L, et al. Male erectile dysfunction: Prevalence and quality of life in the Netherlands: The UREPIC-study. Int J Impotence Res 2000;12:Suppl.5, S8:28.
30. Mahmoud KZ, Azim SA, Gadallah M, et al. A patient based epidemiology study to find the prevalence and correlates of erectile dysfunction (ED) in Egypt. Int J Impotence Res 2000;12:Suppl.5, S24:P46.
31. Koskimaki J, Hakama M, Tammela TLJ. Prevalence of erectile dysfunction in Finland. Int J Impotence Res 2000;12:Suppl.5, S25:P47.
32. Dogunro S, Osegbe D, Jaguste VS, et al. Epidemiology of erectile dysfunction (ED) and its correlates: a patient based study in Nigerian population. Int J Impotence Res 2000;12:Suppl.5, S25:P47.
33. Kadiri N, Berrada S, Tahiri S, et al. Prevalence of erectile dysfunction (ED) and its correlates in Morocco: A population based epidemiology study. Int J Impotence Res 2000;12:Suppl.5, S25:P48.
34. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain.Results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001;166:569-574.
35. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-617.
36. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40-80y: prevalence and correlates identified in the global study of sexual attitudes and behaviour. Int J Impotence Res 2005; 17:39-57.
37. de Boer BJ, Bots ML, Lycklama a Nijeholt AAB, et al. Erectile dysfunction in primary care: relevance and patient characteristics. The ENIGMA study. Int J Impotence Res 2004;16:358-364.
38. Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47:80-86.
39. Glina S, Melo LF, Martins FG, et al. Brazilian survey on aging and sexual performance. 9th World Meeting on Impotence Research, Perth. Int J Impotence Res 2000;12:p. 55:M58.
40. Billups K, Bank AJ, Padma-Nathan H, et al. Erectile dysfunction is a marker for cardiovascular disease: Results of the minority health institute expert advisory panel. J Sex Med 2005;2:40-52.
41. Kumamoto Y, Tsukamoto T, Satoh T, et al. Epidemiological study on aging changes of sexual activity in Japanese men and women. The Aging Male 2000;3:Suppl.1,9 Abstr. 0-18.
42. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). EurUrol 2003;44:637-649.